Back to Search
Start Over
Ovid staff shuffle reads like a who's who of Big Pharma as biotech pivots from Angelman failure
- Source :
- Fiercebiotech.com. July 9, 2021
- Publication Year :
- 2021
-
Abstract
- Byline: Annalee Armstrong After Ovid Therapeutics' lead product failed a phase 3 clinical trial in April, CEO Jeremy Levin knew they had some tough work ahead of them. Now, the [...]
- Subjects :
- Biotechnology
Biotechnology industry
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Fiercebiotech.com
- Publication Type :
- News
- Accession number :
- edsgcl.667925101